Once-weekly exenatide vs once- or twice-daily insulin detemir: randomised, open-label clinical trial of efficacy and safety in patients with Type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas

被引：0
|
作者：
Davies, M. [1 ]
Heller, S. [2 ]
Sreenan, S. [3 ]
Sapin, H. [4 ]
Adetunji, O. [5 ]
Tahbaz, A. [5 ]
Vora, J. [6 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
[3] Connolly Hosp, Royal Coll Surg Ireland, Dublin, Ireland
[4] Lilly France, Suresnes, France
[5] Eli Lilly & Co, Basingstoke, Hants, England
[6] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
DIABETIC MEDICINE | 2013年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [41] Safety of once- daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice
    Ross, Stuart
    Dzida, Grzegorz
    Ji, Qiuhe
    Kaiser, Marcel
    Ligthelm, Robert
    Meneghini, Luigi
    Nazeri, Avideh
    Orozco-Beltran, Domingo
    Pan, Changyu
    Svendsen, Anne Louise
    JOURNAL OF DIABETES, 2014, 6 (03) : 243 - 250
  • [42] Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
    Bajaj, Harpreet S.
    Bergenstal, Richard M.
    Christoffersen, Andreas
    Davies, Melanie J.
    Gowda, Amoolya
    Isendahl, Joakim
    Lingvay, Ildiko
    Senior, Peter A.
    Silver, Robert J.
    Trevisan, Roberto
    Rosenstock, Julio
    DIABETES CARE, 2021, 44 (07) : 1586 - 1594
  • [43] DURATION-8 randomised controlled trial 104-week results: efficacy and safety of once-weekly exenatide (ExQW) plus once-daily dapagliflozin (DAPA) vs ExQWor DAPA alone
    Hardy, E.
    Jabbour, S. A.
    Guja, C.
    Bhattacharya, S.
    Ohman, P. K.
    Frias, J. P.
    DIABETOLOGIA, 2018, 61 : S20 - S20
  • [44] Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial
    Frias, Juan P.
    Hardy, Elise
    Ahmed, Azazuddin
    Ohman, Peter
    Jabbour, Serge
    Wang, Hui
    Guja, Cristian
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1520 - 1525
  • [45] Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial
    Ross, Stuart A.
    Rafeiro, Elizabeth
    Meinicke, Thomas
    Toorawa, Robert
    Weber-Born, Sonja
    Woerle, Hans-Juergen
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (09) : 1465 - 1474
  • [46] Efficacy and safety of switching to insulin icodec, a once-weekly basal insulin, vs insulin glargine U100 in patients with type 2 diabetes inadequately controlled on OADs and basal insulin
    Bajaj, H.
    Isendahl, J.
    Gowda, A.
    Stachlewska, K.
    Rosenstock, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S317 - S317
  • [47] Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes
    Hwang, Y. -C.
    Kang, M.
    Ahn, C. W.
    Park, J. S.
    Baik, S. H.
    Chung, D. J.
    Jang, H. C.
    Kim, K. -A.
    Lee, I. -K.
    Min, K. W.
    Nam, M.
    Park, T. S.
    Son, S. M.
    Sung, Y. -A.
    Woo, J. -T.
    Park, K. S.
    Lee, M. -K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (03) : 236 - 243
  • [48] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
    Aroda, Vanita R.
    Bain, Stephen C.
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Axelsen, Mads
    Rowe, Everton
    DeVries, J. Hans
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05): : 355 - 366
  • [49] Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and/or a Sulfonylurea in Predominantly Asian Patients with Type 2 Diabetes
    Wang, Weiqing
    Ruiz, Luis Nevarez
    Filippova, Ekaterina
    Song, Ki-Ho
    Gu, Liqun
    Li, Pengfei
    Yang, Jun
    DIABETES, 2015, 64 : A74 - A74
  • [50] Efficacy and Safety of Once-Weekly (QW) Albiglutide vs. Once-Daily (QD) Liraglutide in Type 2 Diabetes (T2D) Inadequately Controlled on Oral Agents: Harmony 7 Trial
    Pratley, Richard E.
    Barnett, Anthony
    Feinglos, Marc M.
    Harman-Boehm, Ilana
    Nauck, Michael
    Ovalle, Fernando
    Johnson, Susan
    Stewart, Murray
    Ye, June
    Rosenstock, Julio
    DIABETES, 2012, 61 : A240 - A241
12345